Skip to main content
. 2024 Jul 2;16(8):1957–1980. doi: 10.1038/s44321-024-00094-2

Figure EV1. Modest differences in talazoparib sensitivity observed in vitro compared to in-vivo settings (Fig. 1) in Brca1-def and Bard1-def breast tumor cells.

Figure EV1

(A, B) In vitro cell viability assay comparing the talazoparib sensitivity between talazoparib-sensitive (“Sen”) Brca1-def and Bard1-def breast tumor cells and their talazoparib-resistant (“Res”) derivative lines. Cell viability values are normalized to the DMSO-treated control (considered as 100% live cells) and presented as mean values ± SEM. P values were determined by a two-tailed, unpaired, Welch’s test. For the Brca1-def model, n = 3 for each concentration tested, ** at 0.3 nM indicates P = 0.0028, * at 1 nM indicates P = 0.0104, * at 3 nM indicates P = 0.0104, and * at 100 nM indicates P = 0.0357. For the Bard1-def model, n = 3 for each tested concentration, and * at 3.0 nM indicates P = 0.0256. ns; not significant.